Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials

Justin Ferdinandus, Helen Kaul, Gundolf Schneider, Michael Fuchs, Hans Theodor Eich, Christian Baues, Johannes Rosenbrock, Katrin S Roth, Alexander Drzezga, Lutz Van Heek, Markus Dietlein, Peter Borchmann, Carsten Kobe

Blood (2024) 144 (Supplement 1): 566.

https://doi.org/10.1182/blood-2024-210791

Published: 2024

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Dennis A. Eichenauer, Ina Bühnen, Christian Baues, Carsten Kobe, Helen Kaul, Richard Greil, Alden Moccia, Joseé M. Zijlstra, Bernd Hertenstein, Max S. Topp, Marianne Just, Bastian von Tresckow, Hans-Theodor Eich, Michael Fuchs, Markus Dietlein, Sylvia Hartmann, Andreas Engert, Peter Borchmann

Blood (2023) 142 (6): 553–560.

https://doi.org/10.1182/blood.2023019939

Published: 2023

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Thomas Pabst, Richard Greil, Dennis A. Eichenauer, Max Topp, Marianne Just, Bernd Hertenstein, Valdete Schaub, Martin Vogelhuber, Josée M Zijlstra, Annette Plütschow, Christian Baues, Andreas Rosenwald, Markus Dietlein, Peter Borchmann, Andreas Engert

Blood (2021) 138 (Supplement 1): 2438.

https://doi.org/10.1182/blood-2021-152260

Published: 2021

Journal Articles

AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Stephanie Sasse, MD, Jesko Momotow, MD, Annette Plütschow, Andreas Hüttmann, MD, Nadezda Basara, MD, Christian Koenecke, MD, Sonja Martin, MD, Martin Bentz, MD, Christina Grosse-Thie, MD, Sven Thorspecken, MD, Maike de Wit, MD, Carsten Kobe, MD, Markus Dietlein, MD, Bastian von Tresckow, MD, Michael Fuchs, Peter Borchmann, MD, Andreas Engert, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141250

Published: 2020

Journal Articles

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Conrad-Amadeus Voltin, Jasmin Mettler, MD, Horst Mueller, PhD, Michael Fuchs, MD, Christian Baues, MD, Markus Dietlein, MD, Andreas Engert, MD, Peter Borchmann, MD PhD, Carsten Kobe, Paul J Bröckelmann, MD

Blood (2019) 134 (Supplement_1): 4020.

https://doi.org/10.1182/blood-2019-123641

Published: 2019

Journal Articles

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Michael Fuchs, Helen Goergen, Carsten Kobe, MD, Hans Eich, MD, Christian Baues, MD, Richard Greil, MD, Stephanie Sasse, MD, Josée M Zijlstra, MD, Andreas Lohri, MD, Andreas Rosenwald, Bastian von Tresckow, MD, Volker Diehl, MD, Georg Kuhnert, Markus Dietlein, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2018) 132 (Supplement 1): 925.

https://doi.org/10.1182/blood-2018-99-114519

Published: 2018

Journal Articles

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma

Carsten Kobe, Helen Goergen, Christian Baues, Georg Kuhnert, Conrad-Amadeus Voltin, Josée Zijlstra, Otto Hoekstra, Jasmin Mettler, Alexander Drzezga, Andreas Engert, Peter Borchmann, Markus Dietlein

Blood (2018) 132 (21): 2273–2279.

https://doi.org/10.1182/blood-2018-05-852129

Published: 2018

Journal Articles

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Blood (2017) 130 (Supplement 1): 737.

https://doi.org/10.1182/blood.V130.Suppl_1.737.737

Published: 2017

Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert

Blood (2015) 126 (23): 580.

https://doi.org/10.1182/blood.V126.23.580.580

Published: 2015

Journal Articles

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Georg Kuhnert, Joerg Kessler, Carolin Buerkle, Miroslav Ravic, Stefan Knackmuss, Jens-Peter Marschner, Elke Pogge von Strandmann, Peter Borchmann, Andreas Engert

Blood (2015) 125 (26): 4024–4031.

https://doi.org/10.1182/blood-2014-12-614636

Published: 2015

Journal Articles

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Peter Borchmann, MD, Heinz Haverkamp, Andreas Lohri, MD, Stefanie Kreissl, MD, Richard Greil, MD, Jana Markova, MD, Michaela Feuring-Buske, MD, Julia Meissner, MD, Ulrich Dührsen, Nicole Engel, MD, Ulrich Keller, MD, Georg Maschmeyer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2014) 124 (21): 500.

https://doi.org/10.1182/blood.V124.21.500.500

Published: 2014

Journal Articles

A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Eugene Zhukovsky, PhD, Achim Rothe, MD, Bastian von Tresckow, MD, Max Topp, Anas Younes, MD, Dennis A. Eichenauer, MD, Horst Hummel, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Joerg Kessler, PhD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Poggevon Strandmann, PhD, Andreas Engert, MD

Blood (2013) 122 (21): 5116.

https://doi.org/10.1182/blood.V122.21.5116.5116

Published: 2013

Journal Articles

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Plütschow, PhD, Stefanie Kreissl, MD, Michael Fuchs, MD, Martin Soekler, MD, Nicole Engel, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2013) 122 (21): 4344.

https://doi.org/10.1182/blood.V122.21.4344.4344

Published: 2013

Journal Articles

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

Andreas Engert, MD, Carsten Kobe, MD, Heinz Haverkamp, Georg Kuhnert, Jana Markova, MD, Andreas Lohri, MD, Susanne Klutmann, MD, Holger Amthauer, MD, Volker Diehl, MD, Peter Borchmann, MD, Markus Dietlein, MD

Blood (2012) 120 (21): 3684.

https://doi.org/10.1182/blood.V120.21.3684.3684

Published: 2012

Journal Articles

Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results

Andreas Engert, MD, Heinz Haverkamp, Carsten Kobe, MD, Jana Markova, MD, Christoph Renner, MD, Anthony D. Ho, MD, PhD, Josée Zijlstra, MD, Zdenek Král, MD, Harald Stein, MD, Hans Theodor Eich, MD, Rolf-Peter Müller, MD, Markus Dietlein, MD, Peter Borchmann, MD, Volker Diehl, MD

Blood (2011) 118 (21): 589.

https://doi.org/10.1182/blood.V118.21.589.589

Published: 2011

Journal Articles

A Phase I Study with the Bispecific Anti-CD30 × Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma,

Achim Rothe, MD, Anas Younes, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Dennis A. Eichenauer, MD, Joerg Kessler, Max S. Topp, MD, Horst Hummel, MD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Pogge von Strandmann, PhD, Andreas Engert, MD

Blood (2011) 118 (21): 3709.

https://doi.org/10.1182/blood.V118.21.3709.3709

Published: 2011

Journal Articles

Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

Andreas Engert, MD, Carsten Kobe, Jana Markova, Heinz Haverkamp, Peter Borchmann, Felicitas Hitz, Josee Zijlstra, Hans Eich, Rolf-Peter Mueller, Markus Dietlein, Volker Diehl

Blood (2010) 116 (21): 764.

https://doi.org/10.1182/blood.V116.21.764.764

Published: 2010

Journal Articles

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Blood (2008) 112 (10): 3989–3994.

https://doi.org/10.1182/blood-2008-06-155820

Published: 2008

NARROW

Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results

A Phase I Study with the Bispecific Anti-CD30 × Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma,

Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only